Please ensure Javascript is enabled for purposes of website accessibility

Why Abiomed, Inc. Shares Were Sent Soaring 137% in 2015

By Todd Campbell - Jan 8, 2016 at 3:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Growing use of Impella products in heart surgery is sparking sales and profit.

Image source: Abiomed.

What: Rapidly growing sales of its Impella product line of heart catheters, sensors, and pumps led to shares of Abiomed (ABMD 2.05%) sky-rocketing 137.2% higher last year, according to Capital IQ.

So what: Interventional cardiologists are increasingly relying on Abiomed's medical devices to boost patient blood circulation before, during, and after catheterization lab procedures, and in 2015, the FDA approval of its devices in additional high-risk heart procedures sent revenue zipping 47% higher to $76 million last quarter.

The revenue growth stems from a 48% increase in patient use of the company's products that suggests Abiomed is holding its own against competitors, including Thoratec, which markets Centrimag in the acute setting and was recently acquired by St. Jude Medical (STJ).

Following Abiomed's fiscal Q2 performance, management now expects full-year sales of between $305 million and $315 million. That's up from its previous outlook of between $300 million and $310 million, which was issued after fiscal Q1, and nicely above the guidance for between $285 million and $295 million, which was issued ahead of the fiscal year.

Now what: Abiomed's ability to leverage volume growth into higher profit-friendly margins is intriguing, but the stock is far from cheap.

In fiscal Q2, the company's operating income grew to 16.8% of sales from 8% the year prior, but even with that tailwind, Abiomed's expected EPS of $1.04 next fiscal year (up from $0.69 this fiscal year) means its forward P/E remains a staggering 80.

Because the company is growing quickly, aggressive investors may want to consider this company for portfolios, particularly since St. Jude Medical's acquisition of Thoratec may indicate that an acquirer could come knocking. However, a nose-bleed valuation hints that a lot of that M&A potential is already priced into shares, and for that reason, investors might want to wait for a sell-off before jumping in and buying.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

St. Jude Medical, Inc. Stock Quote
St. Jude Medical, Inc.
STJ
ABIOMED, Inc. Stock Quote
ABIOMED, Inc.
ABMD
$254.29 (2.05%) $5.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.